Devonian Health Group Inc (GSD) - Net Assets
Based on the latest financial reports, Devonian Health Group Inc (GSD) has net assets worth CA$9.60 Million CAD (≈ $6.94 Million USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$15.57 Million ≈ $11.26 Million USD) and total liabilities (CA$5.97 Million ≈ $4.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Devonian Health Group Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$9.60 Million |
| % of Total Assets | 61.66% |
| Annual Growth Rate | 5.82% |
| 5-Year Change | 21.46% |
| 10-Year Change | 121.39% |
| Growth Volatility | 2244.57 |
Devonian Health Group Inc - Net Assets Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Devonian Health Group Inc for the complete picture of this company's asset base.
Annual Net Assets for Devonian Health Group Inc (2015–2025)
The table below shows the annual net assets of Devonian Health Group Inc from 2015 to 2025. For live valuation and market cap data, see GSD stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | CA$9.14 Million ≈ $6.61 Million |
-34.07% |
| 2024-07-31 | CA$13.86 Million ≈ $10.03 Million |
-2.72% |
| 2023-07-31 | CA$14.25 Million ≈ $10.31 Million |
-12.44% |
| 2022-07-31 | CA$16.27 Million ≈ $11.77 Million |
+116.29% |
| 2021-07-31 | CA$7.52 Million ≈ $5.44 Million |
-19.83% |
| 2020-07-31 | CA$9.38 Million ≈ $6.79 Million |
-6.87% |
| 2019-07-31 | CA$10.08 Million ≈ $7.29 Million |
-20.87% |
| 2018-07-31 | CA$12.74 Million ≈ $9.21 Million |
+55.53% |
| 2017-07-31 | CA$8.19 Million ≈ $5.92 Million |
+98.39% |
| 2016-07-31 | CA$4.13 Million ≈ $2.99 Million |
+7812.53% |
| 2016-06-30 | CA$52.16K ≈ $37.73K |
-98.99% |
| 2015-07-31 | CA$5.19 Million ≈ $3.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Devonian Health Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2126.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$42.40 Million | 464.05% |
| Total Equity | CA$9.14 Million | 100.00% |
Devonian Health Group Inc Competitors by Market Cap
The table below lists competitors of Devonian Health Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OCB Bhd
KLSE:5533
|
$20.01 Million |
|
Clean Seas Seafood Ltd
AU:CSS
|
$20.02 Million |
|
Arvee Laboratories (India) Limited
NSE:ARVEE
|
$20.02 Million |
|
Khadim India Limited
NSE:KHADIM
|
$20.02 Million |
|
A Dong Paint JSC
VN:ADP
|
$20.00 Million |
|
Castor Maritime Inc
NASDAQ:CTRM
|
$20.00 Million |
|
Everbright Digital Holding Limited Ordinary Shares
NASDAQ:EDHL
|
$20.00 Million |
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
$19.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Devonian Health Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,859,986 to 9,137,668, a change of -4,722,318 (-34.1%).
- Net loss of 6,012,791 reduced equity.
- New share issuances of 600,000 increased equity.
- Other factors increased equity by 690,473.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-6.01 Million | -65.8% |
| Share Issuances | CA$600.00K | +6.57% |
| Other Changes | CA$690.47K | +7.56% |
| Total Change | CA$- | -34.07% |
Book Value vs Market Value Analysis
This analysis compares Devonian Health Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.70x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 71.74x to 2.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-07-31 | CA$0.14 | CA$10.00 | x |
| 2018-07-31 | CA$0.19 | CA$10.00 | x |
| 2019-07-31 | CA$0.15 | CA$10.00 | x |
| 2020-07-31 | CA$0.11 | CA$10.00 | x |
| 2021-07-31 | CA$0.08 | CA$10.00 | x |
| 2022-07-31 | CA$0.12 | CA$10.00 | x |
| 2023-07-31 | CA$5.92 | CA$10.00 | x |
| 2024-07-31 | CA$5.61 | CA$10.00 | x |
| 2025-07-31 | CA$3.70 | CA$10.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Devonian Health Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -65.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.49%
- • Asset Turnover: 1.49x
- • Equity Multiplier: 1.73x
- Recent ROE (-65.80%) is below the historical average (-49.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 111.16% | 0.00% | 0.00x | 2.26x | CA$5.25 Million |
| 2016 | -330.59% | 0.00% | 0.00x | 1.68x | CA$-177.66K |
| 2016 | -44.17% | 0.00% | 0.00x | 2.44x | CA$-2.24 Million |
| 2017 | -53.44% | 0.00% | 0.00x | 1.41x | CA$-5.19 Million |
| 2018 | -25.03% | -99.60% | 0.17x | 1.50x | CA$-4.46 Million |
| 2019 | -29.57% | -50.18% | 0.35x | 1.70x | CA$-3.99 Million |
| 2020 | -46.62% | -204.13% | 0.13x | 1.78x | CA$-5.31 Million |
| 2021 | -44.48% | -226.92% | 0.10x | 1.94x | CA$-4.10 Million |
| 2022 | -21.19% | -149.59% | 0.11x | 1.33x | CA$-5.08 Million |
| 2023 | -32.28% | -196.11% | 0.12x | 1.35x | CA$-6.02 Million |
| 2024 | -13.18% | -9.46% | 0.63x | 2.22x | CA$-3.21 Million |
| 2025 | -65.80% | -25.49% | 1.49x | 1.73x | CA$-6.93 Million |
Industry Comparison
This section compares Devonian Health Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $25,316,433
- Average return on equity (ROE) among peers: -417.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Devonian Health Group Inc (GSD) | CA$9.60 Million | 111.16% | 0.62x | $20.01 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more